Zydus gets USFDA nod for treatment of HIV infection
DSIJ Intelligence / 08 Aug 2017
Zydus Cadila has received tentative approval from the USFDA to market Abacavir and Lamivudine tablets USP, 600 mg/300 mg.
Zydus Cadila has received tentative approval from the USFDA to market Abacavir and Lamivudine tablets USP, 600 mg/300 mg. The drug is indicated to use in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection and will be produced at the group’s formulation manufacturing facility at the Pharma SEZ in Ahmedabad.
The sales of Abacavir and Lamivudine tablets are estimated at USD 240.2 million. The group has now more than 130 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
Meanwhile, the stock traded in the negative territory, slipping 0.43% at Rs 531.50 per share on the BSE at 1245 hours. On the NSE the stock has attracted a total traded volume of 1,96,767 shares and a total traded value of Rs 1,043.32 lakh.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.